Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Xetra  >  Fresenius SE & Co. KGaA    FRE   DE0005785604

FRESENIUS SE & CO. KGAA

(FRE)
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Fresenius : Kabi Introduces Neostigmine Methylsulfate Injection, USP Simplist Prefilled Syringe in 3 mg per 3 mL Presentation

share with twitter share with LinkedIn share with facebook
share via e-mail
0
06/11/2019 | 10:06am EDT

LAKE ZURICH - Fresenius Kabi announced today the immediate availability in the United States of Neostigmine Methylsulfate Injection, USP in 3 mg per 3 mL Simplist ready-to-administer prefilled syringes.

Fresenius Kabi is a global health company that specializes in medicines and technologies for infusion, transfusion and clinical nutrition.

The Fresenius Kabi Simplist Neostigmine Injection prefilled syringe is the first manufacturer-prepared, ready-to-administer prefilled syringe on the market. Fresenius Kabi has sold Neostigmine Injection, USP in 0.5 mg per 1 mL and 1 mg per 1 mL vial presentations since 2015.

'Fresenius Kabi is pleased to continue the expansion of our convenient Simplist prefilled syringe portfolio,' said John Ducker, president and CEO of Fresenius Kabi USA. 'This is the fourth Simplist product we've introduced this year and represents the strength of our pipeline of important therapies and delivery systems that can help physicians practice more efficiently.'

About Simplist Neostigmine Methylsulfate Injection, USP

Neostigmine Methylsulfate Injection, a cholinesterase inhibitor, is indicated for intravenous use for reversal of the effects of nondepolarizing neuromuscular blocking agents (NMBA) after surgery.

Important Safety Information

An anticholinergic agent, e.g., atropine sulfate or glycopyrrolate, should be administered prior to or concomitantly with neostigmine methylsulfate.

Neostigmine is contraindicated in patients with: Hypersensitivity to neostigmine.

Peritonitis or mechanical obstruction of the urinary or intestinal tracts.

Neostigmine has been associated with bradycardia: Atropine or glycopyrrolate should be administered prior to administration of neostigmine methylsulfate injection to lessen risk of bradycardia.

Coexisting Conditions: Patients with known cardiac disease, cardiac arrhythmias, or recent coronary artery occlusion may be particularly sensitive to the hemodynamic effects of neostigmine; their blood pressure and electrocardiogram should be continuously monitored with the initiation of neostigmine treatment and for a duration sufficient to assure hemodynamic stability.

Neuromuscular Dysfunction: Can occur if large doses of neostigmine methylsulfate are administered when there is minimal neuromuscular blockade; reduce the dose if recovery from neuromuscular blockade is nearly complete.

To report SUSPECTED ADVERSE REACTIONS, contact Fresenius Kabi USA, LLC at 1-800-551-7176, option 5, or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

This Important Safety Information does not include all the information needed to use Neostigmine Methylsulfate Injection, USP safely and effectively.

About Fresenius Kabi

Fresenius Kabi (www.fresenius-kabi.com/us) is a global health care company that specializes in medicines and technologies for infusion, transfusion and clinical nutrition. The company's products and services are used to help care for critically and chronically ill patients. The company's U.S. headquarters is in Lake Zurich, Illinois. The company's global headquarters is in Bad Homburg, Germany.

Contact:

Lake Zurich

Tel: (847) 550-2300

Email: communications.USA@fresenius-kabi.com

(C) 2019 Electronic News Publishing, source ENP Newswire

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on FRESENIUS SE & CO. KGAA
10/16FRESENIUS : celebrates expansion of Bad Homburg headquarters
PU
10/08Deutsche Bank's chairman best paid among German blue chips in 2018
RE
10/07FRESENIUS : Kabi launches Fulvestrant in prefilled syringes in the U.S.
PU
09/30FRESENIUS SE & CO. KGAA : Release according to Article 41 of the WpHG [the Germa..
EQ
09/16FRESENIUS : 2020 DRG inflator for German hospitals set at 3.66%
PU
09/15Fresenius drops possible sale of blood transfusion unit - spokesman
RE
09/13FRESENIUS SE & CO. KGAA : Release according to Article 40, Section 1 of the WpHG..
EQ
09/11FRESENIUS : Helios launches digital portal for patients
PU
09/09FRESENIUS : Medical Care's publishes annual medical report
PU
09/06FRESENIUS : Medical Care builds new laboratory in Mississippi
PU
More news
Financials (EUR)
Sales 2019 35 389 M
EBIT 2019 4 676 M
Net income 2019 1 846 M
Debt 2019 20 659 M
Yield 2019 1,85%
P/E ratio 2019 13,1x
P/E ratio 2020 12,0x
EV / Sales2019 1,27x
EV / Sales2020 1,11x
Capitalization 24 163 M
Chart FRESENIUS SE & CO. KGAA
Duration : Period :
Fresenius SE & Co. KGaA Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends FRESENIUS SE & CO. KGAA
Short TermMid-TermLong Term
TrendsNeutralBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 23
Average target price 56,25  €
Last Close Price 43,37  €
Spread / Highest target 72,5%
Spread / Average Target 29,7%
Spread / Lowest Target -25,2%
EPS Revisions
Managers
NameTitle
Stephan Sturm President & Chief Executive Officer
Gerd Krick Chairman-Supervisory Board
Rachel Clare Empey Chief Financial Officer
Niko Stumpfögger Deputy Chairman-Supervisory Board
Klaus-Peter Müller Member-Supervisory Board
Sector and Competitors